Back to Search
Start Over
Synthesis of 1,2,3-triazole-thymol derivatives as potential antimicrobial agents.
- Source :
-
Heliyon [Heliyon] 2022 Oct 01; Vol. 8 (10), pp. e10836. Date of Electronic Publication: 2022 Oct 01 (Print Publication: 2022). - Publication Year :
- 2022
-
Abstract
- Background: Thymol as a natural biological template can be modified chemically since the hydroxyl group makes it a candidate for structural modification. Thus, this study incorporated the triazole moiety on thymol and the chlorination of thymol moiety to help improve its biological potency.<br />Materials and Methods: A series of ten 1,2,3-triazole-thymol derivatives 1-10 were synthesized from thymol, by a click reaction between O-propargyl terminal alkyne of thymol and its chlorothymol with benzyl azide and substituted benzyl azides. Their structures were confirmed by spectroscopic methods ( <superscript>1</superscript> H-NMR, <superscript>13</superscript> C-NMR, IR, GC-MS-EI/CI and LC-ESI-QTOF-MS). The Well diffusion method using Müeller-Hinton agar plates was used to demonstrate the antimicrobial activities of the synthesized triazole-thymol derivatives on selected bacterial strains; Escherichia coli ATCC 25922, Staphylococcus aureus ATCC25923, Methicillin resistant S. aureus (MRSA), Pseudomonas aeruginosa ATCC 29853, E. coli ESBL, K l ebsiella pneumoniae NCTC 13438 and Meropenem Resistant E. coli.<br />Results: All the synthesized triazole-thymol derivatives showed significant but variable antibacterial activity against the seven medically important bacterial strains tested. The compound 4-((4-chloro-2-isopropyl-5-methylphenoxy)methyl)-1-(2-nitrobenzyl)-1 H -1,2,3triazole (9) demonstrated a higher antibacterial activity with a mean zone of inhibition (38.7 mm) compared with ampicillin as the positive control which gave a zone size of 30.0 mm. In addition, the compound showed a three-fold potency than the parent compound, thymol (11.0 mm) against MRSA at a concentration of 100 μg/ml.<br />Conclusion: These results provide additional evidence of the exploitation of natural products like thymol as leads for drug development against medically important bacterial pathogens.<br />Competing Interests: The authors declare no conflict of interest.<br /> (© 2022 The Author(s).)
Details
- Language :
- English
- ISSN :
- 2405-8440
- Volume :
- 8
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- Heliyon
- Publication Type :
- Academic Journal
- Accession number :
- 36217474
- Full Text :
- https://doi.org/10.1016/j.heliyon.2022.e10836